Eli Lilly and Company (NYSE:LLY) Shares Sold by Arlington Trust Co LLC

Arlington Trust Co LLC decreased its position in Eli Lilly and Company (NYSE:LLY) by 4.7% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 2,467 shares of the company’s stock after selling 122 shares during the period. Arlington Trust Co LLC’s holdings in Eli Lilly and Company were worth $1,905,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. Global Wealth Management Investment Advisory Inc. grew its holdings in Eli Lilly and Company by 0.8% in the fourth quarter. Global Wealth Management Investment Advisory Inc. now owns 6,191 shares of the company’s stock valued at $4,779,000 after purchasing an additional 52 shares during the last quarter. Soltis Investment Advisors LLC grew its holdings in Eli Lilly and Company by 218.9% in the fourth quarter. Soltis Investment Advisors LLC now owns 4,005 shares of the company’s stock valued at $3,092,000 after purchasing an additional 2,749 shares during the last quarter. Quilter Plc boosted its stake in shares of Eli Lilly and Company by 26.4% during the fourth quarter. Quilter Plc now owns 14,353 shares of the company’s stock valued at $11,081,000 after acquiring an additional 2,997 shares during the last quarter. Silicon Valley Capital Partners boosted its stake in shares of Eli Lilly and Company by 4,959.0% during the fourth quarter. Silicon Valley Capital Partners now owns 12,091 shares of the company’s stock valued at $9,334,000 after acquiring an additional 11,852 shares during the last quarter. Finally, Opal Wealth Advisors LLC boosted its stake in shares of Eli Lilly and Company by 10.9% during the fourth quarter. Opal Wealth Advisors LLC now owns 1,016 shares of the company’s stock valued at $784,000 after acquiring an additional 100 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently commented on LLY. StockNews.com raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Friday, February 7th. Citigroup decreased their price objective on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating on the stock in a research note on Tuesday, January 28th. Bank of America reaffirmed a “buy” rating and set a $997.00 price objective on shares of Eli Lilly and Company in a research note on Tuesday, December 10th. Redburn Atlantic raised Eli Lilly and Company to a “hold” rating in a research note on Monday, November 4th. Finally, Barclays decreased their price objective on Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating on the stock in a research note on Thursday, October 31st. Four analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $997.50.

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock opened at $865.13 on Wednesday. The stock’s 50-day moving average is $791.24 and its 200-day moving average is $843.52. The company has a market cap of $821.28 billion, a price-to-earnings ratio of 73.88, a price-to-earnings-growth ratio of 1.87 and a beta of 0.42. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 0.97. Eli Lilly and Company has a 12 month low of $711.40 and a 12 month high of $972.53.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, February 6th. The company reported $5.32 EPS for the quarter, missing analysts’ consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 86.26% and a net margin of 23.51%. Equities analysts anticipate that Eli Lilly and Company will post 23.33 earnings per share for the current year.

Eli Lilly and Company Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, March 10th. Investors of record on Friday, February 14th will be issued a dividend of $1.50 per share. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.30. This represents a $6.00 annualized dividend and a dividend yield of 0.69%. The ex-dividend date of this dividend is Friday, February 14th. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 44.41%.

Eli Lilly and Company announced that its Board of Directors has approved a stock repurchase plan on Monday, December 9th that authorizes the company to buyback $15.00 billion in outstanding shares. This buyback authorization authorizes the company to purchase up to 2% of its stock through open market purchases. Stock buyback plans are generally an indication that the company’s board believes its stock is undervalued.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.